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HDAC8 and STAT3 repress BMF gene activity in colon
cancer cells
Y Kang1, H Nian2, P Rajendran3, E Kim3, WM Dashwood3, JT Pinto4, LA Boardman5, SN Thibodeau5, PJ Limburg5, CV Löhr6,
WH Bisson7, DE Williams1,7, E Ho1 and RH Dashwood*,3,8,9,10
Histone deacetylase (HDAC) inhibitors are undergoing clinical trials as anticancer agents, but some exhibit resistance mechanisms
linked to anti-apoptotic Bcl-2 functions, such as BH3-only protein silencing. HDAC inhibitors that reactivate BH3-only family
members might offer an improved therapeutic approach. We show here that a novel seleno-α-keto acid triggers global histone
acetylation in human colon cancer cells and activates apoptosis in a p21-independent manner. Profiling of multiple survival factors
identified a critical role for the BH3-only member Bcl-2-modifying factor (Bmf). On the corresponding BMF gene promoter, loss of
HDAC8 was associated with signal transducer and activator of transcription 3 (STAT3)/specificity protein 3 (Sp3) transcription
factor exchange and recruitment of p300. Treatment with a p300 inhibitor or transient overexpression of exogenous HDAC8
interfered with BMF induction, whereas RNAi-mediated silencing of STAT3 activated the target gene. This is the first report to
identify a direct target gene of HDAC8 repression, namely, BMF. Interestingly, the repressive role of HDAC8 could be uncoupled
from HDAC1 to trigger Bmf-mediated apoptosis. These findings have implications for the development of HDAC8-selective
inhibitors as therapeutic agents, beyond the reported involvement of HDAC8 in childhood malignancy.
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Histone deacetylase (HDAC) enzymes have been implicated
in both normal physiology and pathophysiology, and several
HDAC inhibitors have entered clinical trials.1–3 These inhibi-
tors include vorinostat, a direct-acting compound that fits the
HDAC active site, and romidepsin, a prodrug that through
reductive metabolism generates a zinc-binding thiol.4
Evaluation of such compounds against solid tumors and
hematological malignancies has provided insights into clinical
efficacy, as well as resistance mechanisms and off-target
effects.1–3
Off-target effects such as cardiotoxicity and thrombocyto-
penia arise from inhibitors acting on multiple HDACs,5,6
whereas resistance has been linked to anti-apoptotic Bcl-2
functions, including BH3-only protein silencing.7–9 HDAC
inhibitors that reactivate BH3-only family members, such as
Bcl-2-modifying factor (Bmf), might offer an improved
therapeutic approach for treating cancer and other conditions.
We previously reported on the HDAC inhibitory activity of
methylselenopyruvate (MSP), a novel seleno-α-keto acid
metabolite generated by transamination of the natural organo-
selenium compound methylselenocysteine (MSC).10–12 MSP
was identified as a competitive inhibitor of HDAC8, and thiswas
supported by molecular modeling studies of MSP/HDAC8
interactions in silico.10
HDAC8 was the first human HDAC to be crystalized with
bound inhibitors,13–16 but it remains one of the least under-
stood HDACs, with no known direct transcriptional target or
corepressor partner.17,18 In pursuing the mechanism of action
of MSP in human colon cancer cells, we identified a key role for
HDAC8 in regulating BMF gene activity and Bmf-mediated
apoptosis. The work provides support for HDAC8 as a relevant
mechanistic target for cancer therapy, beyond its reported
involvement in childhood cancer.19
Results
MSP triggers Bmf-mediated apoptosis independent of
p21 induction. Metabolic conversion of MSC to MSP was
reported previously.11 An inhibitor of aminotransfer reactions
caused a dose-dependent loss of histone acetylation in human
colon cancer cells treated with MSC, but not MSP (Figure 1a).
This was associated with loss of cleaved poly(ADP-ribose)
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polymerase (PARP) and p21 induction by MSC, whereas MSP
was effective in the presence or absence of the transaminase
inhibitor (Figure 1b). HCT116p21+/+ and HCT116p21− /− cells
treated with MSP exhibited similar responses in the MTT
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)
assay (Figure 1c), but p21− /− cells did not accumulate in the
G2/M phase of the cell cycle, unlike p21
+/+ cells (Figure 1d).
Notably, HCT116p21− /− cells had higher levels of cleaved
caspase-3 and cleaved PARP compared with HCT116p21+/+
cells exposed to MSP under the same conditions (Figure 1e).
These findings suggested that p21 induction is necessary for
G2/M arrest, but is not a prerequisite for apoptosis induction
by MSP.
To investigate the apoptotic mechanism in more detail,
several survival factors were profiled. Induction of pro-
apoptotic APAF1, BAK, BIM, and BMF, and loss of anti-
apoptotic BCLXL occurred within 12 h of MSP treatment, in
both HCT116 and HT29 colon cancer cell lines (Figure 2a).
Induction of BMF was particularly striking, and was confirmed
both at the mRNA and protein level in time-course studies
(Figures 2b and c). Knockdown of Bmf using RNAi attenuated
the increase in BMF mRNA levels following MSP treatment
(Figure 2d), and there was a reduction in Bmf protein
expression (Figure 2e). These changes were associated with
reduced PARP cleavage and attenuated levels of cleaved
caspases (Figure 2f). Notably, in cells treated with MSP,
activated caspases 3, 6, and 9 were reduced to near
background levels by Bmf knockdown. Cleaved caspase-8
also was detected after MSP treatment and this caspase
apparently was unaffected by Bmf knockdown (Figure 2f).
Further experiments should seek to optimize Bmf knockdown
beyond the ~ 50–60% reduction achieved here (Figures 2d
and e), and clarify the relative contributions of internal and
external apoptotic pathways. Nonetheless, we conclude that
Bmf was a key mediator of MSP-induced apoptosis in colon
cancer cells.
BMF activation by MSP involves HDAC8 and STAT3
de-recruitment. To prioritize histone marks for BMF chromatin
immunoprecipitation (ChIP) assays, immunoblotting was first
performed on whole-cell lysates of colon cancer cells. At the
early time point of 3 h, MSP increased histone H3 acetylation
(for example, H3acK9,14, H3acK9, and H3acK18) without
dramatic changes in histone H3 methylation or phosphoryla-
tion (Supplementary Figure 1a). Histone H4 hyperacetylation
also was detected within 3 h of MSP treatment, as evidenced
by increased H4acK12 and H4acK5,8,12,16 histone marks
(Supplementary Figure 1b). Time-course studies confirmed
that histone hyperacetylation was maintained for several hours
in response to MSP treatment, and that histone methylation
marks associated with gene activation, such as H3K4me3,
became prominent after 24 h (Supplementary Figure 1c).
These findings indicated that MSP induced global histone
acetylation before alterations in other histone marks.
Because global histone acetylation changes preceded
alterations in other histone modifications, we conducted ChIP
assays in colon cancer cells at an early time point, 4 h.
Consistent with the BMF induction by MSP (Figure 2b), RNA
polymerase II (Pol II) was recruited (Figure 3a) and therewas a
marked increase in local histone acetylation (Figure 3b). In
parallel analyses of BCLXL (Supplementary Figure 2),
reduced histone acetylation and attenuated Pol II levels were
Figure 1 Induction of p21 by MSP is not a prerequisite for apoptosis in colon cancer cells. (a) HCT116 cells were incubated with the transaminase inhibitor aminooxyacetic
acid (AOAA) 1 h before treatment with MSP, MSC, or vehicle (control). Whole-cell lysates were immunoblotted 6 h later for histone H3 acetylation. Wedge symbol indicates
increasing concentration of AOAA. (b) AOAA pretreatment for 1 h blocked p21 induction by MSC and the cleavage of PARP, whereas MSP was unaffected by AOAA. Open arrow,
cleaved PARP. (c) HCT116p21+/+ and HCT116p21− /− cells responded similarly to MSP treatment in MTTassays; mean±S.D., n= 3, *Po0.05 using Students t-test. (d) G2/M
cell cycle arrest at 48 h required the presence of p21. (e) In the absence of p21, MSP strongly increased cleaved caspase-3 and (open arrow) cleaved PARP. Results in a–e are
representative findings from two or more independent experiments
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detected on the corresponding gene promoter after MSP
treatment, consistent with the observed transcriptional down-
regulation of this pro-survival factor (Figure 2a). We did not
examine serine 2-phosphorylated Pol II in association with
BCLXL or BMF, but this might be included in future
experiments.20
The BMF promoter has predicted binding sites for multiple
transcription factors, including Sp1 (specificity protein 1)/Sp3
(specificity protein 3) and signal transducer and activator of
transcription 3 (STAT3). ChIP assays with the corresponding
antibodies failed to identify consistent associations for Sp1,
but upstream of the transcriptional start site there was binding
of Sp3 andSTAT3 (region ‘f’, Figures 3c and d). MSP treatment
enhanced Sp3 and attenuated STAT3 interactions.
A prior report implicated HDAC1 as a repressor of BMF
transcriptional activity.9 We confirmed HDAC1 interactions on
the BMF promoter, slightly upstream of the transcription start
site (peak region ‘e’, Figure 3e). The interactions of HDAC1
with BMF did not appear to be altered by MSP treatment. We
also detected HDAC8 associations under constitutive condi-
tions in colon cancer cells (open bars, peak region ‘h’,
Figure 3f). To our knowledge, BMF is the first identified direct
target gene for HDAC8 repression, none having been reported
before.17 HDAC8 interactions were markedly reduced in
response to MSP treatment (red bars, Figure 3f), and this
coincided with increased histone acetyltransferase (HAT)
p300 interactions (Figure 3g). Immunoblotting of whole-cell
lysates showed no specific loss of HDAC8, or other class I
HDACs, in response to MSP treatment (Supplementary Figure
3). We concluded that HDAC1 and HDAC8might cooperate to
maximally repressBMF, but HDAC8 de-recruitment alonewas
sufficient to activate the target gene.
Inhibition of p300 or overexpression of HDAC8 interferes
with BMF induction. On the basis of the ChIP data (Figures
3f and g), HDAC8 and p300 were examined further as
regulators of BMF transcription. Treatment of colon cancer
cells with a p300 inhibitor attenuated significantly the basal
expression levels as well as the dose-dependent induction of
BMF by MSP (Figure 4a). In transient transfection experi-
ments, forced expression of HDAC8 also interfered with the
ability of MSP to induce the target gene (Figure 4b),
supporting a reciprocal relationship between p300 and
HDAC8 in regulating BMF transcriptional activity. Although
the results in Figure 4a were optimized for the specific p300
inhibitor selected, incomplete reductions in BMF expression
were obtained, suggesting the possible involvement of other
HATs in regulating BMF. Gain- and loss-of-function experi-
ments, including the use of HAT mutants and HDAC8
silencing, might provide additional insights.
HDAC8 and STAT3 cooperate to repress BMF transcription.
To clarify the apparent reciprocal relationship between Sp3
and STAT3 in regulating BMF (Figures 3c and d), we
performed RNAi experiments on the corresponding transcrip-
tion factors. Knockdown of STAT3 increased the constitutive
and MSP-induced levels of BMF, supporting a suppressive
role for STAT3 on the BMF promoter (Figure 5a). Unexpect-
edly, knockdown of Sp3 did not produce a corresponding
decrease in BMF expression, nor was there an apparent
Figure 2 Bmf has a pivotal role in the apoptotic mechanism triggered by MSP. (a) Quantitative real-time PCR (qRT-PCR) assays of survival genes normalized to β-actin
(ACTB), 12 h after treatment of colon cancer cells with MSP (10 μM) or vehicle. Data indicate mean± S.D., n= 3, *Po0.05 using Students t-test to compare MSP-treated cells
with vehicle controls. (b, c) Time-course for induction of BMFmRNA (mean± S.D., n= 3) and Bmf protein expression. (d, e) In HCT116 cells, MSP was significantly less effective
at inducing BMFmRNA (mean± S.D., n= 3, *Po0.05) and Bmf protein expression following siRNA-mediated knockdown of Bmf. (f) Reduced cleavage of caspases and (open
arrow) PARP in MSP-treated HCT116 cells following Bmf knockdown. Results in a–f are representative findings from two or more experiments
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compensatory mechanism involving Sp1 upregulation after
Sp3 silencing (Figure 5a). These results suggested a
possible ‘bystander’ effect in which Sp3 interacts with a
cognate binding site that becomes unmasked following
STAT3 de-recruitment, without necessarily activating the
target gene. We conclude that in addition to STAT3 and
Sp3, other factors regulate BMF transcriptional activity on
HDAC8 release, possibly in association with HDAC1.
Finally, HDAC8 was immunoprecipitated from whole-cell
lysates of HCT116 cells and immunoblotted for potential
protein partners. No interaction with Sp3 was detected, but a
band corresponding to STAT3 was identified (Figure 5b, open
arrow). To our knowledge, this is the first evidence reported for
a protein partner in the HDAC8 corepressor complex.17
Notably, the STAT3 band was detected in the presence and
absence of MSP treatment (Figure 5b), suggesting that an
HDAC8/STAT3 corepressor complex might be released from
the BMF promoter to recruit p300 and other coactivators
(Figure 6).
Discussion
The first X-ray crystallography structures published of a
human HDAC, HDAC8,13,14 provided valuable insights into
the catalytic mechanism and binding characteristics of various
inhibitors. A decade later, surprisingly little information was
available on the role of HDAC8 in physiology or pathophysiol-
ogy. HDAC8 associates with α-actin and regulates smooth
muscle contractility,21 as well as influencing human myome-
trial activity via the acetylation of heat–shock protein 20.22
Other class I HDACs (HDAC1, HDAC2, and HDAC3) are
known to associate with gene promoters in repressor
complexes, but promoter interactions with HDAC8 have not
been reported, nor have regulatory gene targets of HDAC8
been clearly described.17 We now report, for the first time, that
HDAC8 can associate with the BMF gene under constitutive
conditions in colon cancer cells, and establish a pro-survival
scenario via the repression of Bmf protein levels.
The increase in global histone acetylation in colon cancer
cells treated with MSP was recapitulated in several other
cancer cell lines. For example, time-course studies in BE(2)C
neuroblastoma cells revealed a rapid induction of histone
acetylation by MSP compared with MSC parent compound
(Supplementary Figure 4a). Interestingly, MSC, MSP, and the
structural analog β-keto-methylselenobutyrate (KMSB) also
induced global histone acetylation in prostate, breast, lung,
and leukemia cells, whereas selenomethionine (SM) had no
such effect (Supplementary Figure 4b). Unlike MSC, SM is a
poor substrate for aminotransferase activity.12 In a pilot study
in vivo, we observed that dietary MSC, but not SM, inhibited
mouse colon tumor multiplicity, and this was associated with
increased Bmf expression and histone acetylation in the
tumors, without marked changes in overall HDAC8 protein
levels (Supplementary Figure 5). We are now seeking to test
the in vivo efficacy of MSP and KMSB along with the
corresponding parent compounds as inducers of Bmf. Further
insights also might come from ChIP assays following treat-
ment with MSC and a transaminase inhibitor, such as
aminooxyacetic acid (AOAA; Figure 1); however, such
experiments would have to be optimized to account for the
Figure 3 HDAC8 is a repressor of the BMF gene. Primers were designed to
interrogate different regions of the BMF gene, including the promoter (hatched box)
and flanking sequences. (a) MSP treatment enhanced RNA Pol II recruitment and
(b) local histone acetylation levels. (c) MSP increased Sp3 transcription factor
binding, adjacent to the transcription start site (arrow), and (d) reduced STAT3
associations. (e) HDAC1 interactions with the BMF promoter were unaffected by MSP
treatment. (f) HDAC8 was present on BMF under constitutive conditions and was
de-recruited following MSP treatment, coincident with increased p300 associations
(g). ChIP assays were conducted at 4 h in HCT116 cells treated with MSP (+MSP) or
vehicle (−MSP). Data were normalized to input controls; H3acK9,K14 also was
normalized to histone H3. Results in a–g indicate mean± S.D., n= 3, from a single
experiment that was repeated on three or more separate occasions
Figure 4 Inhibition of p300 and HDAC8 overexpression interferes with BMF
transcription. (a) Pretreatment of colon cancer cells with p300 inhibitor C64646 (10 μM)
reduced the constitutive levels of BMF and interfered with induction of the target gene by
MSP. (b) Forced expression of HDAC8 by transient transfection rescues cells from BMF
induction by MSP. In a, b, bars indicate mean±S.D., n= 3, from a single experiment
that was repeated at least twice (*Po0.05, by Student’s t-test)
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time taken to convert MSC to MSP at levels that might inhibit
HDAC activity.10,11 We did not specifically examine changes in
BMF expression or HDAC promoter occupancy in other cell
lines shown (Supplementary Figure 4), or in colon cancer cells
other than HCT116 and HT29 (Figure 2a). Such experiments
might help to clarify the working model proposed here.
A notable feature of the working model for MSP (Figure 6) is
the continued interaction of HDAC1 on the BMF promoter
following the release of HDAC8. Time-course ChIP assays
might indicate whether HDAC1 is released at later times,
perhaps coinciding with the appearance of activating histone
methylation marks, such as H3K4me3 (Supplementary Figure
1c). It would be interesting to assess whether, over time, other
HDACs substitute at the position normally occupied by the
HDAC8 complex to downregulate the target gene. This could
have implications for therapeutic strategies selectively target-
ing HDAC8 versus other HDACs. HDAC8 alone was impli-
cated in the pathogenesis of neuroblastoma,19 but multiple
HDACs are dysregulated in most other cancers.17,18 ChIP/re-
ChIP assays in the presence of agents such as etinostat,
which preferentially target class I HDACs other than HDAC8,17
might provide insights into the roles of HDAC1, HDAC2, and
HDAC3 in regulating BMF expression in the absence of
HDAC8. Studies with other HDAC inhibitors also might identify
changes in the composition of the corepressor complex that
mask specific HDAC associations, rather than necessarily
triggering HDAC release from the BMF gene promoter.
In the case of vorinostat (suberoylanilide hydroxamic acid,
SAHA), BMF was highly induced compared with MSP under
the same conditions at 4 h, and there was de-recruitment of
both HDAC1 and HDAC8 (Supplementary Figure 6). SAHA is
an established ‘pan-HDAC’ inhibitor,17,18 whereas MSP has
10-fold greater inhibitory activity toward HDAC8 than
HDAC1.10 Molecular modeling revealed that residue W141
in HDAC8 is replaced by L141 in HDAC1, and this results in
less favorable docking of MSP in the active site
(Supplementary Figure 7). We speculate that structural
features allow MSP to preferentially target HDAC8 for release
according to the working model (Figure 6), whereas pan-
HDAC inhibitors like SAHA de-recruit both HDAC1 and
HDAC8 corepressor complexes to maximally induce the
BMF target gene (Supplementary Figure 8).
ChIP assays also revealed that SAHA had little effect on
Sp3 interactions, whereas STAT3 levels were markedly
reduced on the BMF promoter (Supplementary Figures 6c
and d, black versus white bars, region ‘f’). These findings
further support the ‘bystander’ role of Sp3, proposed above,
and the repressive actions of STAT3 on the target gene. Co-IP
experiments identified amodest increase in STAT3 acetylation
following MSP and SAHA treatment (Supplementary Figure
9a), suggesting a possible role for post-translational modifica-
tions to STAT3. However, in HCT116 cells expressing knock-in
mutants of STAT3, a STAT3 phosphorylation mutant that
interferes with DNA interactions23 consistently enhanced the
basal levels of BMF, whereas a STAT3 acetylation mutant24
Figure 5 STAT3 associates with HDAC8 and represses BMF transcription. (a) siRNAswere used to target STAT3, Sp1, or Sp3, with transfection reagent (mock) and untreated
controls (Ctrl) included in the experiment. After 48 h RNAi knockdown, cells were treated with MSP or vehicle for 12 h and BMF expression was determined relative to ACTB.
Data=mean± S.D., n= 3, from a single experiment that was repeated twice (*Po0.05, by Student’s t-test). Knockdown of STAT3, Sp1, and Sp3 was confirmed by
immunoblotting (IB). (b) Immunoprecipitation (IP) with HDAC8 antibody followed by IB with the corresponding antibodies identified a band for STAT3 (open arrow) but not Sp3 or
Sp1 (data not shown). Results are representative of the findings from three independent experiments
Figure 6 Model for HDAC regulation of BMF transcriptional activity. MSP inhibits HDAC8 more effectively than HDAC1,10 which triggers the release of a corepressor complex
comprising HDAC8, STAT3, and other partners. Release of the HDAC8 corepressor complex recruits p300, Sp3, and other factors that drive RNA Pol II activity
HDAC8 repression of BMF
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had less impact on the target gene (Supplementary Figure
9b). Interestingly, in all three cell lines, there was a comparable
time-dependent increase in BMF expression that plateaued
between 6 and 24 h after MSP treatment (Supplementary
Figure 9b). We interpret these data as evidence that, beyond
STAT3 post-translational modifications, HDAC8 inhibition and
de-recruitment likely serves as the primary driver of BMF
transcriptional activity in response to MSP.
Prior work established that the silencing of HDAC8 by RNAi
activated apoptosis and/or inhibited the growth of human
cancer cells.25,26 No significant changes in BMFmRNA levels
were detected after treatment of colon cancer cells with
5-aza-2ʹ-deoxycytidine (Supplementary Figure 10), implying
that DNA promoter methylation did not have a critical
role in silencing BMF transcription under the conditions
reported here.
Finally, the current findings provide possible new leads
for understanding the biological roles of HDAC8 in
schistosomiasis,27 chronic obstructive pulmonary disease,28,29
and skull morphogenesis.30,31 Interestingly, novel mutations
affecting HDAC8 and EP300 recently were linked to the
development of Cornelia de Lange syndrome (CdLS), Rubin-
stein–Taybi syndrome, and other congenital abnormalities.32–35
Loss-of-function HDAC8 mutations in six CdLS probands
increased the acetylation and loading onto chromatin of
SMC3, a ‘cohesin’ that has a role in regulating gene
expression.32 Another member of the cohesin complex, NIPBL
(nipped-B-like), is commonlymutated in patientswith CdLS, and
the corresponding loss-of-function zebrafish embryos have
increased apoptosis in developing neural tissues.34 Chemical
activation of the pathway in nipblb-loss-of-function embryos
rescued the adverse phenotypes and restored the physiological
levels of cell death.34 This is consistent with the working model
proposed here (Figure 6), in which functional HDAC8associates
with, and represses, pro-apoptotic BMF, whereas loss-of-
function HDAC8 mutants would aberrantly activate apoptosis
and have deleterious consequences during embryo develop-
ment. On the basis of the results presented here, we speculate
that dysregulation of Bmf-mediated apoptosis might have a
critical role in CdLS and related syndromes.
Materials and Methods
Cell culture. HCT116p21+/+ and HCT116p21− /− cells were provided by Dr. Bert
Vogelstein (Johns Hopkins University, Baltimore, MD, USA). Dr. Zhenghe Wang
(Case Western Reserve University, Cleveland, OH, USA) kindly supplied HCT116
cells expressing acetylation and phosphorylation mutants of STAT3.23,24 All other cell
lines were obtained from ATCC (Manassas, VA, USA) and were cultured under the
conditions described elsewhere.36–43 Chemicals were from the sources
reported10,11,43 and were added to cells at the following nominal concentrations,
unless stated otherwise: MSP (10 μM), MSC (50 μM), KMSB (10 μM), SM (50 μM),
and SAHA (3 μM). In some experiments, 0, 0.1, 0.5, or 2 mM concentrations of
AOAA (Sigma, St. Louis, MO, USA) were added 1 h before other test compounds to
inhibit the transamination reaction.44,45 Other experiments used a p300 inhibitor46
(10 μM C646, Sigma), added to cells 30 min before MSP treatment, or DNA
methyltransferase inhibitor 5-aza-2ʹ-deoxycytidine, as reported.40 Cells were
collected at the times indicated in the figures.
Cell viability and cell cycle analyses. MTT assays and fluorescence-
activated cell sorting analyses were conducted according to the basic protocols
reported elsewhere.47,48
Western blot. Whole-cell lysates were immunoblotted using the methodology
described elsewhere.36,37 Primary antibodies were to the following acetylated (ac),
methylated (me), and phosphorylated (ph) histone marks: H3K9me3, H3K4me2,
H4acK12, and H4acK5,K8,K12,K16 (Upstate, Temecula, CA, USA); H3acK9,K14,
H3acK9, and H3S10ph (Cell Signaling, Beverly, MA, USA); H3K27me3, H3K4me3,
H3S28ph, and H3T3ph (Active Motif, Carlsbad, CA, USA); and H3acK18 (Abcam,
San Francisco, CA, USA). Other primary antibodies were to histone H3 and histone
H4 (Upstate, Cell Signaling, Active Motif); PARP, p21, Bmf, cleaved caspase-3,
cleaved caspase-6, cleaved caspase-8 and cleaved caspase-9 (Cell Signaling);
HDAC8 (R&D Systems, Minneapolis, MN, USA); HDAC1 and p300 (Santa Cruz
Biotechnology, Dallas, TX, USA); and β-actin (Sigma). Antibodies to p53,
acetylated p53, α-tubulin, acetylated α-tubulin, STAT3, Sp1, and Sp3 were as
reported.10,11,36,37,48–51
Knockdown and overexpression experiments. HDAC8 overexpres-
sion was achieved by transient transfection of 0.5 μg HDAC8 construct or empty
vector (OriGene, Rockville, MD, USA), using the protocol reported before for HDAC3
and HDAC6.36 In knockdown studies, cells were transfected with Bmf siRNA
(SASI_Hs01_00127817, Sigma) or negative control siRNA (Universal Negative
control #1, Sigma) using Lipofectamine RNAiMAX (Invitrogen, Carlsbad, CA, USA),
according to the manufacturer’s instructions. After 48 h, cells were treated with MSP
or vehicle and collected at 12 h. RNAi also was used as reported48–51 to knockdown
Sp1, Sp3, and STAT3.
Real-time RT-PCR and qPCR. Methodologies for RNA extraction, cDNA
synthesis, and qPCR were reported before.10,40,41 PCR reactions were performed
on a Roche Light Cycle 480 II instrument (Roche, Indianapolis, IN, USA). Primers
were to the following targets: BMF, BCL2, BCLXL, BAX, BAK, BIM, APAF1, and
P21WAF1. Targets were normalized to internal controls indicated in the figures.
Chromatin immunoprecipitation. After treatment with MSP or vehicle for
4 h, cells were incubated with 1% formaldehyde in cell culture medium for 10 min at
room temperature, and then the reaction was stopped with 0.12 M glycine for 5 min.
DNA shearing and ChIP used the ChIP-IT Express Enzymatic (Active Motif) kit,
following the recommended protocol. In the IP step, anti-histone H3, anti-H3acK9,
K14 (Cell Signaling), and anti-RNA polymerase II (Active Motif) were incubated
overnight at 4 °C. Additional IP experiments used antibodies to Sp1, Sp3, STAT3,
HDAC8, HDAC1, and p300 (from sources listed above). After eluting pull-down DNA
from magnetic beads, DNA purification used the QIAquick PCR Purification kit
(Qiagen, Valencia, CA, USA). Quantification of immunoprecipitated and input
(control) DNA was carried out by qPCR on a Light Cycler 480 II (Roche), with Light
Cycle 480 SYBR Green I Kit master (Roche). The primer sequences are available
on request.
Molecular modeling, docking, and pocket binding prediction.
The 3D coordinates of the human catalytic domain of HDAC8 in the inhibited
conformation and HDAC1 in the active conformation were retrieved from the Protein
Data Bank (PDB 1T67 and 4BKX, respectively). The human catalytic domain of
HDAC1 in the inhibited conformation was built through homology modeling using
PDB 1767 as a starting template (Molsoft ICM 3.7-2 d, Molsoft, San Diego, CA,
USA).52 Models were energetically refined in the internal coordinate space with
Molsoft ICM.36,53 Five types of interaction potential were considered: (i) van der
Waals potential for a hydrogen atom probe; (ii) van der Waals potential for a heavy-
atom probe (generic carbon of 1.7 Å radius); (iii) optimized electrostatic term;
(iv) hydrophobic terms; and (v) loan pair-based potential, which reflects directional
preferences in hydrogen bonding. Energy terms were based on the Merck molecular
force field to account for solvation free energy and entropic contribution. Modified
intermolecular terms, such as soft van der Waals, hydrogen bonding, and
hydrophobic terms, were included in the analyses. Conformational sampling is based
on the biased probability Monte Carlo procedure, which randomly selects a
conformation in the internal coordinate space and then moves randomly to a new
position independent of the previous one, according to a predefined continuous
probability distribution. After each random step, full local minimization improves the
efficiency of the procedure. In the ICM-VLS (Molsoft ICM) screening procedure,
ligand scoring is optimized to obtain maximal separation between binders and
non-binders. Ligand was assigned a score according to its fit within the protein,
accounting for electrostatic, hydrophobicity, and entropy parameters.36,53 The
protocol was first validated by docking trichostatin A into the binding site and
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reproducing the crystallographic pose in HDAC8 (PDB 1T64). Binding-pocket
volumes were predicted using Pocket Finder (Molsoft ICM 3.7-d).54,55
Statistical analyses. Unless indicated otherwise data were expressed
as mean± S.D. (n= 3). Paired comparisons were made using Student’s t-test.
A P-valueo0.05 was considered as statistically significant, and indicated as such
with an asterisk in the corresponding figures.
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